Tvardi Therapeutics (NASDAQ:TVRD) Posts Earnings Results, Misses Estimates By $0.08 EPS

Tvardi Therapeutics (NASDAQ:TVRD) issued its quarterly earnings data on Friday. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08), FiscalAI reports.

Tvardi Therapeutics Stock Down 0.7%

Shares of NASDAQ TVRD opened at $4.18 on Friday. The business’s 50 day moving average is $3.44 and its two-hundred day moving average is $3.94. The company has a market cap of $39.21 million, a P/E ratio of -0.75 and a beta of 0.30. Tvardi Therapeutics has a 12 month low of $2.75 and a 12 month high of $43.65.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in Tvardi Therapeutics in the 4th quarter worth approximately $55,000. Quadrature Capital Ltd bought a new position in Tvardi Therapeutics in the 4th quarter worth approximately $90,000. Russell Investments Group Ltd. increased its position in Tvardi Therapeutics by 1,351.5% in the 4th quarter. Russell Investments Group Ltd. now owns 15,966 shares of the company’s stock worth $69,000 after buying an additional 14,866 shares during the period. Squarepoint Ops LLC increased its position in Tvardi Therapeutics by 534.3% in the 4th quarter. Squarepoint Ops LLC now owns 51,783 shares of the company’s stock worth $223,000 after buying an additional 43,619 shares during the period. Finally, Arax Advisory Partners increased its position in Tvardi Therapeutics by 277.2% in the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after buying an additional 6,173 shares during the period. 44.66% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Lucid Cap Mkts raised Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. BTIG Research reissued a “buy” rating and issued a $15.00 price objective on shares of Tvardi Therapeutics in a research note on Wednesday, April 1st. Wall Street Zen downgraded Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Tvardi Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $55.50.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.